Syngene International Shares Plunge After Q4 Earnings Disappoint Investors: A Closer Look at What Went Wrong
In a jarring turn of events for the Indian pharmaceutical and biotechnology sector, Syngene International, a renowned name in contract research, development, and manufacturing, witnessed a sharp drop of nearly 13% in its share price following the release of its Q4 results for FY2024–25. The company, which operates as a subsidiary of Biocon Limited, released … Read more